Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Drew, W L; Miner, R C; Busch, D F; Follansbee, S E; Gullett, J; Mehalko, S G; Gordon, S M; Owen, W F et al. · J Infect Dis · 1991

prospective_cohort · Level II

Where this comes from

Abstract

Seventy-two AIDS patients treated with ganciclovir for cytomegalovirus (CMV) disease were prospectively monitored for the development of drug-resistant virus. No resistant strains were found in 31 patients before therapy or among seven culture-positive patients treated for less than or equal to 3 months. Of 13 culture-positive patients treated for greater than or equal to 3 months, 5 excreted virus resistant (ED50, greater than 12 microM, or ED90, greater than 30 microM) to ganciclovir. Thus, 38% of patients and receiving ganciclovir for greater than 3 months and excreting virus or, overall, 7.6% of the patients were excreting CMV resistant to the drug.

Medical subject headings